Thyrocare Technologies Limited

BSE: THYROCARE539871ISIN INE594H01019

Healthcare
Healthcare Service Provider
BSE 1000

BSE listing

Share price

₹555.90-4.05 (-0.72%)

as of 18 Sep 2026

52W high: ₹1,613.90
52W low: ₹342.55
Off 52W high: -65.56%
1M return: -4.48%
3M return: +2.95%
6M return: +57.52%
1Y return: -53.49%
20D avg volume: 24,947
50 DMA: ₹576.31
200 DMA: ₹482.48

Key ratios Consolidated

Market cap: ₹8,848 Cr
Current price: ₹555.90
52W high / low: ₹1,613.90 / ₹342.55
Face value: ₹10.00
P/E: 50.30
P/B: —
EPS (TTM): ₹11.05
Book value / share: —
ROE: —
ROCE: 33.60%
Operating margin: —
Net margin: —
Debt / equity: 0.00
Net debt: ₹-38.32 Cr
Interest cover: 76.53
Dividend yield: 2.52%
Dividend / share (TTM): ₹14.00
Payout: 126.70%
Cash conversion cycle: 25.0 days

About

In plain English

Thyrocare is a diagnostic company that runs a network of 44 labs across India, processing over 1,375 different medical tests—from routine blood work to advanced genetic sequencing like whole exome analysis. Most of its business comes from partnering with small local collection centres (mom-and-pop clinics, nursing homes) and online health platforms: for example, a local clinic sends a patient's blood sample to Thyrocare, which runs the test and returns the results. They also offer home sample collection for direct customers. Thyrocare focuses on making quality diagnostics affordable at scale, and its customers include franchisees, online aggregators, corporate wellness programmes, and doctors. The company makes money by charging a fee for each test processed through its franchise and partnership channels, which together account for 95% of pathology revenue.

AI-generated summary, written from the company's own filings and disclosures. Every figure elsewhere on this page comes from exchange data, not from a model. See our editorial standards. Generated 23 Jul 2026.

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	240.02	223.95	195.53	216.53	193.03	187.16	165.92	177.36	156.91	154.25	134.74	148.00
	4.15	4.31	4.98	3.05	4.65	4.59	4.01	2.60	3.62	3.49	2.73	2.17
	176.59	164.41	159.24	157.28	147.45	143.93	141.84	142.90	126.62	134.62	117.69	122.26
	61.88	56.42	47.07	59.81	55.41	48.71	44.79	50.12	44.65	46.12	38.01	43.08
	0.03	0.77	0.04	0.21	0.07	0.46	0.20	1.28	0.06	1.06	0.68	0.38
	39.61	36.07	35.76	33.23	33.00	33.47	35.09	29.49	28.72	26.57	26.36	27.06
	1.35	1.52	-0.09	0.59	0.78	0.70	0.60	0.76	0.99	1.12	1.07	1.13
	12.49	14.03	21.63	11.51	11.41	13.77	17.06	13.07	11.36	13.06	13.47	10.65
	60.98	56.11	54.74	51.89	46.63	46.52	43.94	48.59	40.09	47.30	38.37	39.78
	67.58	63.85	41.27	62.30	50.23	47.82	28.09	37.06	33.91	23.12	19.78	27.91
	0.00	0.00	-6.16	0.00	0.00	0.00	0.00	0.00	0.00	-0.22	0.00	0.00
	67.58	63.85	35.11	62.30	50.23	47.82	28.09	37.06	33.91	22.90	19.78	27.91
	16.96	15.73	7.34	14.77	12.19	25.62	8.97	10.35	9.61	5.72	5.17	7.94
	51.33	48.70	28.05	47.81	38.29	21.57	18.96	26.42	23.94	17.18	14.74	20.33
	3.23	2.99	1.82	9.05	7.35	4.17	3.58	4.99	4.52	3.54	2.78	3.84
Key metrics
	81.42	79.40	56.65	74.40	62.42	62.29	45.75	50.89	46.26	37.08	34.32	39.69
	33.90%	35.50%	29.00%	34.40%	32.30%	33.30%	27.60%	28.70%	29.50%	24.00%	25.50%	26.80%
	21.40%	21.70%	14.30%	22.10%	19.80%	11.50%	11.40%	14.90%	15.30%	11.10%	10.90%	13.70%
	—	10.30%	—	11.30%	—	8.50%	—	—	—	—	—	—
	24.30%	19.70%	17.80%	22.10%	23.00%	21.30%	23.10%	19.80%	—	—	—	—
	34.10%	125.80%	47.90%	81.00%	59.90%	25.60%	28.60%	30.00%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	876.03	829.04	687.35	571.88	526.67	588.86	494.62	433.20	402.91	356.31	306.81
	16.49	16.99	14.83	9.37	8.42	29.25	12.43	7.73	9.95	23.00	9.09
	657.52	628.38	555.30	485.66	447.68	390.21	354.52	294.44	275.46	232.12	206.48
	225.18	218.71	188.27	164.51	156.92	166.25	162.53	114.92	108.46	92.19	81.55
	1.05	1.09	2.00	2.47	6.11	4.32	1.09	2.25	2.33	2.41	—
	144.67	138.06	126.77	107.86	106.15	61.13	58.07	48.92	43.35	35.34	—
	3.37	2.80	3.05	4.20	2.35	2.37	0.87	1.85	0.61	0.43	—
	59.66	58.58	55.26	47.01	38.71	33.87	30.28	31.91	26.17	—	—
	223.72	209.37	179.14	159.89	137.24	123.15	101.40	94.67	94.80	81.28	—
	235.00	217.65	146.88	95.59	87.41	227.90	152.53	146.49	137.40	147.19	109.42
	-6.16	-6.16	0.00	0.00	0.00	0.00	0.00	-6.58	0.00	-2.19	0.00
	228.84	211.49	146.88	95.59	87.41	227.90	152.53	139.91	137.40	145.00	109.42
	54.80	50.03	54.69	26.49	24.23	51.58	39.32	52.01	52.92	51.72	38.45
	175.89	162.85	90.75	69.49	64.36	176.14	113.14	88.41	85.14	93.28	70.97
	17.09	10.27	17.13	13.42	12.16	33.30	21.41	16.74	15.95	—	—
Key metrics
	291.87	272.87	205.19	146.80	128.47	264.14	183.68	173.67	164.18	145.43	109.42
	33.32%	32.90%	29.90%	25.70%	24.40%	44.90%	37.10%	40.10%	40.70%	40.80%	35.70%
	20.08%	19.60%	13.20%	12.20%	12.20%	29.90%	22.90%	20.40%	21.10%	26.20%	23.10%
	—	33.60%	26.30%	—	—	—	—	—	—	—	—
	—	20.60%	20.20%	8.60%	-10.60%	19.10%	14.20%	7.50%	13.10%	16.10%	—
	—	79.40%	30.60%	8.00%	-63.50%	55.70%	28.00%	3.80%	-8.70%	31.40%	—
	—	192.36	146.43	—	—	—	—	—	—	—	—
	—	1.31	2.11	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	-38.32	-17.68	—	—	—	—	—	—	—	—
	—	25.0	23.0	—	—	—	—	—	—	—	—
Balance sheet
	—	747.22	692.75	—	—	—	—	—	—	—	—
	—	372.29	337.72	—	—	—	—	—	—	—	—
	—	38.32	17.68	—	—	—	—	—	—	—	—
	—	73.88	73.00	—	—	—	—	—	—	—	—
	—	48.46	46.54	—	—	—	—	—	—	—	—
	—	28.04	25.19	—	—	—	—	—	—	—	—
	—	205.62	148.71	—	—	—	—	—	—	—	—
	—	65.37	76.21	—	—	—	—	—	—	—	—
	—	109.91	121.84	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	586.02	547.05	—	—	—	—	—	—	—	—
Cash flow
	—	213.24	191.32	—	—	—	—	—	—	—	—
	—	-23.01	-52.52	—	—	—	—	—	—	—	—
	—	-169.59	-130.42	—	—	—	—	—	—	—	—
	—	20.88	44.89	—	—	—	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	225.66	210.67	182.48	202.23	178.89	173.87	152.55	163.05	143.63	141.23	122.89	136.29
	3.51	3.72	3.43	2.28	3.96	4.54	3.51	2.12	3.17	2.81	2.09	1.82
	162.54	152.41	143.32	143.62	131.94	130.61	128.12	124.83	111.66	118.99	104.22	109.98
	58.86	54.27	44.61	57.12	52.37	46.19	42.05	46.94	42.11	43.60	35.99	40.70
	0.03	0.77	0.04	0.21	0.07	0.46	0.20	1.28	0.06	1.06	0.68	0.38
	37.16	33.44	32.78	31.37	30.70	31.33	32.96	27.69	26.57	25.12	25.06	25.87
	1.26	1.43	-0.47	0.60	0.62	0.60	0.48	0.63	0.93	0.94	0.96	1.02
	11.23	12.94	19.58	9.70	8.95	11.78	15.34	9.94	9.45	10.41	10.90	9.30
	53.76	50.07	46.69	44.58	39.08	39.95	36.92	38.77	31.79	38.47	30.90	32.53
	66.63	61.98	42.59	60.89	50.91	47.80	27.94	40.34	35.14	25.05	20.76	28.13
	0.00	0.00	-5.97	0.00	0.00	0.00	—	—	—	—	—	—
	66.63	61.98	36.62	60.89	50.91	47.80	27.94	40.34	35.14	25.05	20.76	28.13
	16.46	18.40	10.47	17.86	14.86	25.85	8.71	10.75	9.99	5.82	5.87	7.84
	50.17	43.58	26.15	43.03	36.05	21.95	19.22	29.59	25.15	19.23	14.89	20.29
	3.15	2.75	1.64	8.12	6.80	4.08	3.53	5.59	4.75	3.63	2.81	3.83
Key metrics
	79.12	76.35	55.73	71.19	60.48	60.18	43.76	50.91	45.52	36.40	32.62	38.45
	35.10%	36.20%	30.50%	35.20%	33.80%	34.60%	28.70%	31.20%	31.70%	25.80%	26.50%	28.20%
	22.20%	20.70%	14.30%	21.30%	20.20%	12.60%	12.60%	18.10%	17.50%	13.60%	12.10%	14.90%
	—	10.30%	—	11.30%	—	8.60%	—	—	—	—	—	—
	26.10%	21.20%	19.60%	24.00%	24.50%	23.10%	24.10%	19.60%	—	—	—	—
	39.20%	98.50%	36.10%	45.40%	43.30%	14.10%	29.10%	45.80%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	821.04	774.27	633.10	524.02	486.46	561.53	474.27	400.00	370.28	331.79	300.06
	12.94	13.39	13.34	7.18	5.39	7.40	12.28	10.48	13.66	23.63	8.08
	601.89	571.29	495.23	432.98	410.78	361.55	325.27	254.15	237.08	205.27	194.84
	214.86	208.37	177.28	155.39	150.06	161.79	159.18	110.17	103.25	88.07	78.38
	1.05	1.09	2.00	2.47	6.11	4.32	1.09	2.25	2.33	2.41	8.64
	134.75	128.29	118.56	102.92	102.61	58.82	56.79	45.75	40.51	32.49	29.35
	2.82	2.18	2.63	3.73	2.25	2.38	0.66	1.32	0.47	0.40	—
	53.45	51.17	46.52	39.11	34.08	28.47	21.08	19.54	14.47	12.08	11.69
	195.10	180.42	147.43	129.64	115.47	106.65	86.19	75.20	76.31	69.45	67.65
	232.09	216.37	151.21	98.22	81.07	207.38	161.28	156.33	146.86	150.16	113.30
	-5.97	-5.97	0.00	—	—	—	—	-44.33	—	-2.19	—
	226.12	210.40	151.21	98.22	81.07	207.38	161.28	112.00	146.86	147.96	113.30
	63.19	61.59	55.43	27.08	24.10	55.33	41.51	32.68	51.63	51.93	38.45
	162.93	148.81	95.78	71.14	56.97	152.05	119.77	79.32	95.23	96.04	74.85
	15.66	9.36	17.95	13.44	10.77	28.75	22.66	15.02	17.84	—	—
Key metrics
	282.39	263.75	200.36	141.06	117.40	238.23	183.02	132.86	161.80	160.44	124.99
	34.39%	34.10%	31.60%	26.90%	24.10%	42.40%	38.60%	33.20%	43.70%	48.40%	41.70%
	19.84%	19.20%	15.10%	13.60%	11.70%	27.10%	25.30%	19.80%	25.70%	28.90%	24.90%
	—	34.50%	27.20%	—	—	—	—	—	—	—	—
	—	22.30%	20.80%	7.70%	-13.40%	18.40%	18.60%	8.00%	11.60%	10.60%	—
	—	55.40%	34.60%	24.90%	-62.50%	27.00%	51.00%	-16.70%	-0.80%	28.30%	—
	—	187.14	143.81	—	—	—	—	—	—	—	—
	—	1.38	1.99	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	-32.88	-15.18	—	—	—	—	—	—	—	—
	—	28.7	25.9	—	—	—	—	—	—	—	—
Balance sheet
	—	711.21	676.35	—	—	—	—	—	—	—	—
	—	315.81	298.56	—	—	—	—	—	—	—	—
	—	32.88	15.18	—	—	—	—	—	—	—	—
	—	69.53	68.94	—	—	—	—	—	—	—	—
	—	46.56	45.70	—	—	—	—	—	—	—	—
	—	29.04	26.93	—	—	—	—	—	—	—	—
	—	171.96	113.66	—	—	—	—	—	—	—	—
	—	55.13	69.60	—	—	—	—	—	—	—	—
	—	95.43	110.96	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	560.68	537.10	—	—	—	—	—	—	—	—
Cash flow
	—	206.07	190.76	—	—	—	—	—	—	—	—
	—	-20.92	-54.70	—	—	—	—	—	—	—	—
	—	-167.45	-124.44	—	—	—	—	—	—	—	—
	—	18.93	46.95	—	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +16.76%
Sales CAGR 5Y: +10.30%
Sales CAGR 10Y: —
Profit CAGR 3Y: +37.72%
Profit CAGR 5Y: +4.44%
Profit CAGR 10Y: —
Sales YoY (TTM): +22.84%
Profit YoY (TTM): +52.54%

Consolidated

Sales CAGR 3Y: +16.33%
Sales CAGR 5Y: +10.88%
Sales CAGR 10Y: —
Profit CAGR 3Y: +36.27%
Profit CAGR 5Y: +7.56%
Profit CAGR 10Y: —
Sales YoY (TTM): +21.09%
Profit YoY (TTM): +67.13%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 60.92%

Holder	Type	Holding	Previous	Change
Docon Technologies Private Limited	Promoter	60.92%	—	—
Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund	Public	5.99%	—	—
Icici Prudential Pharma Healthcare And Diaganostics (P.H.D) Fund	Public	5.57%	—	—
Hsbc Mutual Fund - Hsbc Midcap Fund	Public	3.84%	—	—
Aditya Birla Sun Life Trustee Private Limited A/C - Aditya Birla Sun Life Elss Tax Saver Fund	Public	3.15%	—	—
API Holdings Limited	Promoter Group	0.00%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 08, 2026 for Docon Technologies ....9 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for API Holdings Ltd4 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
Please find enclosed herewith copies of Newspaper Publications published on September 04, 2026 in Business Standard (English) and Lakshadeep (Marathi)4 Sep 2026 · Company Update / Newspaper Publication
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for API Holdings Ltd4 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Please find enclosed the Intimation regarding approval of Scheme of Amalgamation of Docon Technologies Private Limited with API Holdings Limited1 Sep 2026 · Company Update / General
Please find enclosed the Intimation regarding complete discharge and release of Transaction Documents pursuant to full redemption and repayment of Non-Convertible Debentures by API Holdings Limited19 Aug 2026 · Others
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd19 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Docon Technologies Pvt Ltd & PACs18 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Docon Technologies Pvt Ltd18 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HSBC Mutual Fund18 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 13, 2026 for Docon Technologies Pvt Ltd18 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Docon Technologies Pvt Ltd & PAC18 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 17, 2026 for Docon Technologies Pvt Ltd17 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Please refer the enclosed intimation letter17 Aug 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund14 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd14 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Docon Technologies Pvt Ltd13 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Docon Technologies Pvt Ltd & PACs13 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Please refer the enclosed intimation letter.13 Aug 2026 · Company Update / General
Please find the attached disclosure received from Docon Technologies Private Limited ("Promoter") for release of pledge on equity shares of the Company13 Aug 2026 · Company Update / General
Please find attached the Earnings Call Transcript held on July 23, 202627 Jul 2026 · Company Update / Earnings Call Transcript
Thyrocare Technologies Limited has informed the exchange regarding submission of machine-readable document of earlier submitted results of the Company for the quarter ended on June 30, 202624 Jul 2026 · Company Update / General
Please find attached herewith Newspaper Publication of Unaudited Financial Results for the quarter ended on June 30, 202624 Jul 2026 · Company Update / Newspaper Publication
Audio Recording of Earnings Conference Call for the quarter ended on June 30, 202623 Jul 2026 · Company Update / General
Please refer the enclosed intimation regarding the in-principle approval of the Board of Directors of the Company for evaluation of the proposed restructuring of the radiology business ....23 Jul 2026 · Company Update / General
Please find attached the Intimation regarding the re-appointment of the Internal Auditor of the Company.23 Jul 2026 · Company Update / General
Please find attached the Investor Presentation on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended on June 30, 202623 Jul 2026 · Company Update / Investor Presentation
Please find attached the Press Release on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended on June 30, 202623 Jul 2026 · Company Update / Press Release / Media Release
Please find enclosed the unaudited standalone and consolidated financial results of the Company for the quarter ended on June 30, 202623 Jul 2026 · Result / Financial Results
Please find enclosed outcome of the Board Meeting held on July 23, 2026, inter alia, approving the unaudited financial results for the quarter ended June 30, 2026, as detailed in the enclosed letter.23 Jul 2026 · Board Meeting / Outcome of Board Meeting
Thyrocare Technologies Limited cordially invites you to its "Earning Call" to be held on Thursday, July 23, 2026 at 06.00 P.M. to discuss the financial performance of the company for Q1 FY27.16 Jul 2026 · Company Update / Analyst / Investor Meet
Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2026 ,inter alia, to consider and approve Unaudited Standalone ....16 Jul 2026 · Board Meeting / Board Meeting
Please find attached herewith Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 20267 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed intimation regarding Amendments to Memorandum of Association of the Company.30 Jun 2026 · Company Update / Amendments to Memorandum & Articles of Association
Please find enclosed intimation regarding change in Statutory Auditors of the Company30 Jun 2026 · Company Update / General
Proceedings of the 26th Annual General Meeting held on 30th June, 2026. Further the scrutinizer''s report along with voting results is enclosed.30 Jun 2026 · AGM/EGM / AGM
Please find attached the Intimation for Closure of Trading Window24 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Please find enclosed communication sent to shareholders for deduction of tax on dividend.10 Jun 2026 · Company Update / General
Please find attached herewith copies of Newspaper Publications published on June 05, 2026, in Business Standard (English) and Navshakti (Marathi)5 Jun 2026 · Company Update / Newspaper Publication
Please find attached letter sent to members of the Company providing web link for the AGM Notice and Annual report for the FY 2025-264 Jun 2026 · Company Update / General

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 7.0000	23 Jun 2026	23 Jun 2026	—
Bonus issue 2:1	28 Nov 2025	28 Nov 2025	—
Interim Dividend - Rs. - 7.0000	24 Oct 2025	24 Oct 2025	—
Final Dividend - Rs. - 21.0000	25 Jul 2025	25 Jul 2025	—
Final Dividend - Rs. - 18.0000	16 Aug 2024	16 Aug 2024	—